

## Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2018

(Pursuant to Article L.233-8 II of the French Commercial Code  
and articles 221-1 and 223-16 of the General Regulations of the *Autorité des Marchés Financiers*)

Charenton-le-Pont, France (July 4, 2018 – 6.00 p.m.) – As of June 30, 2018, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

June 30, 2018

Shares outstanding	219,140,639
Exercisable voting rights	234,313,134
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights*	235,649,964

(\*) Shares held by the Company.

### About Essilor

Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, Bolon™ and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit [www.essilor.com](http://www.essilor.com).

The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

-----  
**Investor Relations and Financial Communications**

Phone: +33 (0)1 49 77 42 16